Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Feb 24, 2020
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
Feb 13, 2020
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
Feb 06, 2020
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Jan 08, 2020
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
Nov 26, 2019
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Nov 25, 2019
Alkermes Completes Acquisition of Rodin Therapeutics
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Nov 18, 2019
Alkermes to Acquire Rodin Therapeutics
Nov 12, 2019
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)
Nov 12, 2019
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
Nov 08, 2019
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Nov 04, 2019
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 23, 2019
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
Oct 21, 2019
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
Oct 16, 2019
Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
Oct 07, 2019
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
Sep 26, 2019
Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 13, 2019
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.